Amgen: ABP 798 Shows Clinical Equivalence To Rituxan In Clinical Study

(RTTNews) - Amgen (AMGN) and Allergan plc (AGN) said a clinical study demonstrated clinical equivalence of ABP 798 to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. In the study, the overall response rate by week 28 was within the prespecified margin for ABP 798.

Safety and immunogenicity of ABP 798, a biosimilar candidate, were comparable to Rituxan. The comparative clinical study was the second of two studies to support regulatory submissions for ABP 798.

In 2011, Amgen and Allergan plc formed a collaboration to develop and commercialize oncology antibody biosimilar medicines.